16 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
on pharmacologic treatment. If approved, the prospect that paltusotine can offer an innovative, once-daily oral alternative represents a significant step
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Regulation FD Disclosure
6:05am
of carcinoid syndrome, as well as advance the rest of our innovative pipeline of internally discovered investigational compounds for people who live with other
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
. The Innovation Passport enables Crinetics to access the Innovative Licensing and Access Pathway (ILAP). The ILAP aims to reduce the time to market
8-K
EX-99.1
you ru71m1nyw69axj
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
EX-99.1
cb92 k8xi41n746
10 Aug 21
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results
4:05pm
8-K
EX-99.1
0phxbyhn3m36q7wypa
3 Sep 20
Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors
7:35am
10-K
54fqgf4zd664 al
13 Mar 19
Annual report
4:06pm
424B4
weexdbbo3d
18 Jul 18
Prospectus supplement with pricing info
5:27pm
S-1/A
5pmmgkbj0txtpatoxs
9 Jul 18
IPO registration (amended)
6:10am
S-1
tc99t0
22 Jun 18
IPO registration
4:07pm
DRS/A
9h58ex9
11 Jun 18
Draft registration statement (amended)
12:00am
DRS
8627p53xro1gfj
3 May 18
Draft registration statement
12:00am
- Prev
- 1
- Next